News
News
Oncopole congratulates the recipients of the CEO scholarship competition
Oncopole congratulates the recipients of the CEO scholarship competition

20 March 2018

Montreal, March 20th 2018 – Oncopole and IRICoR have joined forces to launch the Scholarship Competition – Entrepreneurship in Oncology (CEO), offering the next generation of scientists an opportunity to participate in the first edition of the Life Sciences Entrepreneurship Development Program.

This practical and immersive training was launched in 2018 through a partnership between Montréal InVivo, Université de Montréal’s Faculty of Pharmacy and Concordia University’s John Molson Executive Centre, in collaboration with IRICoR, in order to develop their entrepreneurial skills in life sciences. The program participants will undergo over 150 hours of management training to increase their knowledge on strategy development for innovative companies.

IRICoR and Oncopole proudly awards 8 scholarships to PhD students and post-doc in the field of oncology: Nezahat Ozlem Arat (IRIC/University of Montreal); Simon Beaudoin (University of Sherbrooke); Milad Dagher (McGill University); Jacqueline Ha (Jewish General Hospital, McGill University); Christina Mastromonaco (MUHC, McGill University); Laura Simon (IRIC/University of Montreal); Mona Wu (Jewish General Hospital, McGill University); et Yu Zhan (CRCHUM).

Nadine Beauger, Chief Executive Officer at IRICoR, wishes to congratulate the recipients and is proud that her oganisation can make a tangible contribution to the training of the next generation of scientists. “The development of entrepreneurship skills is key to the future of our field. I am convinced that the first scholarships recipients will make the most of the program as well as benefit from each other’s already extensive expertises.”

Mrs. Stéphanie Lord-Fontaine, Executive Director of Oncopole, points out “the excellence and the diversity of path followed by selected candidates” and she is convinced “that this cohort promesses to be very dynamic”.

About Oncopole

Oncopole is Quebec’s hub for research, development and investment to accelerate the fight against cancer. Created in February of 2017, it is the product of a unique co-creation process led by the Fonds de recherche du Québec – Santé (FRQS) and made possible by an initial $15M investment from Merck Canada. Oncopole’s mission is to act as a catalyst leveraging actions made by the key players in Quebec’s oncology and innovation research ecosystem. As a result, it aims to position the province as a leader in the field. Its priorities of action, namely research, entrepreneurship, commercialization and integration of innovation, as well as clinical relevance, are orchestrated in order to foster the mobilization of stakeholders, the discovery of innovative approaches to fight cancer and, ultimately, a positive impact for the benefit of patients. For more information about Oncopole, go to: oncopole.ca

About d’IRICoR (Institute for Research in Immunology and Cancer – Commercialization of Research)

As Université de Montréal’s drug discovery and project maturation cluster, IRICoR is a not-for-profit organization based at the Institute for Research in Immunology and Cancer (IRIC), with the mandate to accelerate the discovery, development and commercialization of novel therapies in cancer, immunotherapy and related fields. Since its creation in 2008, IRICoR successfully invests in and supports cutting-edge projects with disruptive potential to rapidly translate innovation into patient-accessible therapies, through either co-development partnerships with industry or company creation. IRICoR seamlessly integrates business-related expertise with industry-level drug discovery in a world-renowned research institute, providing academics with access to a full drug discovery chain with one of the largest academia-based medicinal chemistry groups in Canada. For more information about IRICoR, go to: iricor.ca